InflaRx Unveils Promising Preclinical Findings for INF904
InflaRx Showcases New Developments for INF904
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company known for its innovative anti-inflammatory therapeutics that target the complement system, recently revealed exciting preclinical findings for its oral C5aR inhibitor, INF904. This announcement was made during the 2024 European Meeting on Complement in Human Diseases (EMCHD) held in Lübeck, Germany, where industry experts gathered to discuss advancements in the field of inflammation.
Leadership Engagement at EMCHD
Members of InflaRx's leadership team actively participated in a satellite symposium, addressing the critical role of the C5a/C5aR1 axis in inflammation. They also contributed to discussions on the importance of targeting C3 and C5 as part of inflammation treatment strategies. Additionally, the company hosted a lunch seminar that provided insights into C5a/C5aR inhibition and its potential applications in human diseases.
Insights from the Chief Medical Officer
Dr. Camilla Chong, Chief Medical Officer of InflaRx, expressed enthusiasm about the preclinical data presented at EMCHD 2024. She stated, “We welcome the opportunity to demonstrate our commitment to advancing the science of complement inhibition. The findings emphasize our goal of developing leading anti-inflammatory therapies through C5a and C5aR inhibition.” This preclinical evidence highlights INF904's significant anti-inflammatory capabilities and robust pharmacokinetic properties.
Understanding INF904's Mechanism
Within the study, INF904 was characterized as a highly selective and potent inhibitor of C5aR1, displaying impressive pharmacokinetic (PK) attributes. In controlled tests, INF904 exhibited a 96.5% inhibition of C5a-induced neutropenia, outperforming avacopan, which achieved a 51.1% inhibition at the same dosage. Furthermore, INF904's PK profile was notably superior, revealing 2- to 5-fold higher drug exposure across various animal models compared to avacopan, indicating a promising therapeutic outlook.
Pharmacological Characterization of INF904
The findings further demonstrated that INF904 has a much weaker inhibition of CYP3A4/5 enzymes, crucial for metabolizing many medications, such as glucocorticoids. This property suggests that INF904 may offer a safer alternative in terms of drug interactions, which is particularly significant for patients requiring multiple therapies.
Potential of INF904 in Inflammatory Diseases
INF904 is not only a groundbreaking C5a receptor antagonist but also shows promising effects in various inflammatory disease models. The results from in vitro and in vivo assessments reveal that INF904 effectively reduces neutrophil activation, a key contributor to inflammation. In both whole blood disease models and hamster models, the compound successfully decreased neutrophil influx and improved relevant biochemical indicators, showcasing its potential in therapeutic applications.
Therapeutic Effects Demonstrated
In clinical observations, INF904 has shown significant improvements in metabolic markers such as CREA and BUN levels. These therapeutic effects highlight the extensive potential of INF904 as an anti-inflammatory treatment, aligning with ongoing efforts to develop advanced therapies for conditions driven by excessive inflammation.
About InflaRx: A Commitment to Innovation
Founded in 2007, InflaRx is dedicated to discovering and developing potent anti-inflammatory agents by leveraging its proprietary technologies. Its lead product candidate, vilobelimab, has already demonstrated clinical efficacy and has gained attention in various studies. InflaRx continues to forge ahead with its research initiatives, including further development of INF904, which is positioned as a pioneering oral treatment option.
Contact Information
For further inquiries, reach out to InflaRx N.V. or its partner MC Services AG via the following:
InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
Frequently Asked Questions
What is INF904?
INF904 is an orally administered small molecule that acts as a C5a receptor antagonist, showing promise in reducing inflammation.
How was INF904 evaluated?
INF904's effects were assessed through various preclinical models, including in vivo assessments and cell-based assays.
What sets INF904 apart from other treatments?
Its selective inhibition of C5aR1 and minimal impact on crucial metabolic enzymes such as CYP3A4/5 suggest lower potential for drug interactions.
What are the anticipated benefits of INF904?
The findings indicate strong anti-inflammatory effects, particularly in neutrophil-driven inflammatory responses, making it a hopeful candidate for further clinical exploration.
How does InflaRx plan to progress with INF904?
InflaRx is committed to advancing INF904 through continued research and development, aiming for clinical applications in inflammatory diseases.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Global PET-CT Scanner Market Set for $4.9 Billion Growth
- Yukon Metals Unveils Promising Gold and Copper Discovery
- Coloplast A/S Share Trading Insights for Board and Executives
- BW Offshore Adjusts Convertible Bonds for Shareholders' Dividend
- Procaps Group Outlines Strategic Vision for Future Success
- CenExel Launches Advanced PET Scan Unit for Research
- Healthcare Mobility Solutions Market Foresees Major Growth
- Affiliated Network Providers and Aurora Health Join Forces
- Caristo Diagnostics Recognized as a Quarterfinalist for Digital Health Award
- Plumas Bank Unveils 2024 Corporate Citizenship Insights
- Fortun Advance Reports Rapid Asset Growth and Appoints New VP
- Semnur Pharmaceuticals and Denali Capital to Merge for Growth
- ThreatHunter.ai Launches Free Cybersecurity Tool for Businesses
- G2 Goldfields Unveils Exciting Drilling Results at OKO
- RDE, Inc. Changes Ticker Symbol to GIFT for Growth
- Veterinary Point of Care Diagnostics Market Forecast Growth
- NMI Holdings, Inc. Investor Day Scheduled for November 2024
- LM Funding America, Inc. Gears Up for H.C. Wainwright Conference
- Mount Logan Capital Inc. Expands Workforce with New Hire
- Weatherford Strengthens Digital Portfolio with Datagration Deal
- CVRx Expands Board with New Appointments for Growth
- VCI Global Secures $18 Million Contract for IPO Listings
- Trust Stamp's Direct Offering Brings $2 Million for Growth
- Krispy Krunchy Chicken® Unveils Exciting $4 Meal Deal
- Haivision MCS Secures $61.2M Contract with US Navy for Video Systems
Recent Articles
- Sustainable Apparel Market Projected to Hit USD 24.53 Billion
- Ignitis Group Greenlights 174 MW Solar Project in Latvia
- Trio Petroleum Corp Boosts Oil and Gas Reserves Estimates
- Significant Growth in Methanol Market Projected by 2033
- Pneumococcal Vaccine Market to Reach USD 14.78 Billion by 2034
- Alexandria Real Estate Equities Announces Q3 2024 Results Call
- Enviri Corporation Prepares for Key Investor Conferences
- 4DMT Engages at 2024 Cantor Global Healthcare Conference
- Denali Therapeutics Plans Accelerated Approval for DNL310
- Is Norwegian or Carnival Cruise Line Stock the Better Buy?
- Elevai Labs Inc. Unveils Promising Hair Restoration Data
- Ecopetrol S.A. Announces Management Changes and New Roles
- TopBuild CEO to Speak at Jefferies Industrials Conference
- TransUnion CEO to Speak at Barclays Global Financial Conference
- Lowe's Companies: A Smart Investment as Elections Approach
- Chris Ramirez Joins mesur.io as New VP of Sales to Drive Growth
- Market Trends: Insights from a Leading Financial Strategist
- Growth Prospects: ESR Analyzers Market Expected to Expand
- Turmalina Metals Corp Secures Approval for Colquemayo Project
- Exploring Future Potential: CrowdStrike and Amazon Securities
- Protein Bars Market to Reach USD 2.8 Billion by 2034
- GC Biopharma Partners with Hanmi to Advance Fabry Treatment
- TECNO x GEEKOM Unveils MEGAMINI G1: A Gaming Revolution
- Kronos Advanced Technologies Announces Special Cash Dividend
- Kalmar and Volvo Penta Join Forces in Engine Service Agreement